How Eli Lilly Became the First Trillion-Dollar Healthcare Company With AI

Eli Lilly’s rise to a $1 trillion market valuation marks a defining moment in the global pharmaceutical industry. No healthcare company had crossed that threshold before. Lilly reached it in a year shaped by surging demand for its GLP-1 medicines, expanding AI partnerships, new internal computing infrastructure, and a growing network of research collaborations.

Lilly’s valuation milestone follows unprecedented commercial activity around its GLP-1 portfolio. The company’s weight-loss therapy Zepbound and diabetes treatment Mounjaro continue to experience exceptional demand across markets. These medicines sit within one of the fastest-growing therapeutic categories worldwide, and their uptake has transformed Lilly into the most valuable pharmaceutical company in history.

The company’s record valuation also places renewed attention on the Lilly Endowment, its largest shareholder. The foundation holds more than 92 million shares, valued at roughly $102 billion based on mid-week trading. With that asset base, the Endowment remains the largest private foundation in the United States and continues to fund education, community development and religious initiatives, especially in Indiana.

In the same period, Novo Nordisk, Lilly’s closest GLP-1 competitor has experienced a 45% decline in share price, driven in part by disappointing results from an Alzheimer’s trial. Lilly’s stock, meanwhile, has climbed more than 37% this year. Analysts expect ongoing expansion in global obesity and diabetes markets, positioning GLP-1 therapies among the industry’s most significant revenue generators.